SCHEMBL2678249

SCHEMBL2678249

CN(C)c1ccc(C(=O)N2CCCN(C(=O)O)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.58
ALDH1A1 P00352 6/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
LMNA P02545 1/20 0.54
HTT P42858 1/20 0.54
HPGD P15428 6/20 0.53
POLB P06746 1/20 0.50
GPR183 P32249 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MAPK1 P28482 1/20 0.49
ABL1 P00519 1/20 0.48
BCR P11274 1/20 0.48
USP2 O75604 1/20 0.47
L3MBTL3 Q96JM7 1/20 0.47
NAMPT P43490 1/20 0.46
AVPR2 P30518 1/20 0.46
AVPR1A P37288 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1376416 0.95 GPR183 (0.53) CNR2ALDH1A1SMN1; SMN2HPGDPOLB
SCHEMBL24783903 0.89 HPGD (0.68) CNR2ALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL2455541 0.87 HPGD (0.71) CNR2ALDH1A1KMT2AMEN1LMNA
SCHEMBL2676774 0.82 ALDH1A1 (0.66) ALDH1A1KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL2678752 0.80 HPGD (0.75) ALDH1A1SMN1; SMN2HPGDPOLBMAPK1
SCHEMBL2677366 0.79 ALDH1A1 (0.58) ALDH1A1KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL3451002 0.79 L3MBTL3 (0.51) CNR2ALDH1A1KMT2AHTTHPGD
SCHEMBL2677804 0.79 KMT2A (0.71) ALDH1A1KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL11390513 0.78 GPR183 (0.50) CNR2ALDH1A1HPGDPOLBGPR183
SCHEMBL1374701 0.78 SIGMAR1 (0.62) CNR2ALDH1A1HPGDGPR183ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173638-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-08 US claimed
US-20100009964-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 US claimed
WO-2008064054-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-29 WO claimed
US-8173638-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-08 US disclosed
US-20100009964-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 US disclosed
WO-2008064054-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009964-A1 Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 CNR2 1/4885ALDH1A1 1695/4885KMT2A 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.